三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
戈利昔替尼与其它JAK抑制剂的选择性比较
戈利昔替尼与其它JAK抑制剂的选择性比较
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:94KB
图片尺寸:1107*707
同报告图片
/
4
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
fCDkuq7ngrkxIHwg5Lqu54K5MiB8IOS6rueCuTMgfAp8LS0tLS0tLXwtLS0tLS0tfC0tLS0tLS18Cnwg6Z225ZCR5YyF5ousRUdGUiBFeG9uMjBpbnPnqoHlj5jlnKjlhoXnmoTlpJrnp41FR0ZS56qB5Y+Y5Lqa5Z6LIHwg5L+d55WZ5a+5RUdGUuaVj+aEn+eqgeWPmOWPilQ3OTBN56qB5Y+Y55qE5oqX6IK/55ik5rS75oCnIHwg5pS55ZaE6I2v5Luj5Yqo5Yqb5a2m77yM5Lq65L2T5Y2K6KGw5pyf6ZW/6L6+57qmNTDlsI/ml7bvvIzmr4/ml6XkuIDmrKHlj6PmnI3lrp7njrDmjIHnu63nqLPlrprmipHliLYgfAoK6LWE5paZ5p2l5rqQ77ya5Yy76ISJ6YCa77yM5Zu95YWD6K+B5Yi456CU56m25omA
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
所属报告:
迪哲医药-公司深度报告:小分子创新能力突出商业化前景良好-250617(24页).pdf
打包全文图表
相关数据
JAK抑制剂在骨髓纤维化治疗中的竞争格局
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
收藏
竞争格局
2026-06-26
原图定位
查看详情
《KAT6抑制剂化合物、药物组合物及其制备方法和N-(6-((1H-pyrazol-1-yl)methyl)-4-metho
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
收藏
行业数据
2026-05-11
原图定位
查看详情
图10、全球PD-(L)1抑制剂市场规模(十亿美元)
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
收藏
市场规模
2026-05-11
原图定位
查看详情
图10.VMAT2抑制剂全球销售情况(亿美元)
收藏
行业数据
2026-04-20
原图定位
查看详情
全球PCSK9抑制剂市场规模(亿美元)
fCDlubTku70gICB8IOWFqOeQg1BDU0s55oqR5Yi25YmC5biC5Zy66KeE5qih77yI5Lq/576O5YWD77yJIHwgWW9ZICAgfAp8LS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tfAp8IDIwMTYgICB8IDMgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgLSAgICAgfAp8IDIwMTcgICB8IDUgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgODAlICAgfAp8IDIwMTggICB8IDEwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMTAwJSAgfAp8IDIwMTlFICB8IDE1ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgNTAlICAgfAp8IDIwMjBFICB8IDIyICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgNDclICAgfAp8IDIwMjFFICB8IDMxICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgNDElICAgfAp8IDIwMjJFICB8IDQwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMjklICAgfAp8IDIwMjNFICB8IDUyICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMzAlICAgfAp8IDIwMjRFICB8IDY1ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMjUlICAgfAp8IDIwMjVFICB8IDc4ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMjAlICAgfAp8IDIwMjZFICB8IDg3ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMTIlICAgfAp8IDIwMjdFICB8IDk1ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgOSUgICAgfAp8IDIwMjhFICB8IDEwMSAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgNiUgICAgfAp8IDIwMjlFICB8IDEwNSAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgNCUgICAgfAp8IDIwMzBFICB8IDEwOCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMyUgICAgfAoK6LWE5paZ5p2l5rqQ77ya5ZCb5a6e55Sf54mp5oub6IKh6K+05piO5Lmm77yM5byX6Iul5pav54m55rKZ5Yip5paH
收藏
市场规模
2026-04-13
原图定位
查看详情
中国PCSK9抑制剂市场规模(亿人民币)
收藏
市场规模
2026-04-13
原图定位
查看详情
相较于PD-(L)1抑制剂,PD-(L)1/VEGF双抗有极大替代和拓展空间
收藏
行业数据
2026-03-31
原图定位
查看详情
METHANOL 在阳光下选择性转化为氢气的国际合作
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
收藏
行业数据
2026-03-13
原图定位
查看详情
全球在研FXI/FXIa抑制剂的临床进展
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
收藏
行业数据
2026-02-26
原图定位
查看详情
FXI/FXIa抑制剂全球可触及患者数
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
收藏
行业数据
2026-02-26
原图定位
查看详情
图表11FDA获批KRASG12C抑制剂的全球销售额(百万美元)
收藏
行业数据
2026-02-25
原图定位
查看详情
图表19KRASG12D抑制剂竞争格局
收藏
竞争格局
2026-02-25
原图定位
查看详情
图3 mCRC中EGFR抑制剂的美国收入(2004-2017)
收藏
行业数据
2026-02-13
原图定位
查看详情
选择性儿童中枢神经系统肿瘤的发病率和5年总生存率 神经系统肿瘤:2000–2022
收藏
行业数据
2026-02-13
原图定位
查看详情
“预计2026年的B2B环境将为私募股权提供一个更健康、更可预测的环境,尽管仍会保持选择性。”
收藏
行业数据
2026-02-13
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
根据迪哲医药 2025 年 3 月公告,与其他 JAK 抑制剂相比,戈利昔替尼靶点特异性和药代动力学特征更好。戈利昔替尼抑制 JAK 家族其他酪氨酸激酶成员所需 IC50 是抑制 JAK1 所需 IC50 的 200 倍以上;戈利昔替尼半衰期在 45-50 小时左右,PK 个体间差异小,有利于剂量的预测以达到良好的安全、获益平衡。
行业数据
原图定位
当前图表所属:
迪哲医药-公司深度报告:小分子创新能力突出商业化前景良好-250617(24页).pdf
公司高管履历
舒沃替尼分子式及结构设计亮点
中国EGFRex20insNSCLC新发患者数量
全球EGFRex20insNSCLC新发患者数量
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》